peptidylprolyl isomerase A pseudogene 82Genealiases: []
Q-omics provides the consensus-scored PPIAP82 profile across patient tissues and cancer cell-line models. PPIAP82 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPIAP82 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PPIAP82 RNA expression shows 14,279 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where PPIAP82 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP82 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP82 survival associations across molecular data types. PPIAP82 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP82 RNA expression–survival associations across cancer types. High PPIAP82 expression shows unfavorable associations in ACC, UVM, STAD, UCEC, LUAD and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPIAP82 RNA expression.
This table summarizes PPIAP82 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP82. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP82 shows higher tumor expression in KIRC, KIRP, BRCA, BLCA, LIHC and CHOL. The KIRC box plot shows higher PPIAP82 RNA expression in tumor versus normal tissue (log2 FC = +0.169, t-test p < 0.001).
This table shows molecular features associated with PPIAP82 in patient tissues and cancer cell lines. In patient samples, PPIAP82 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
